Remove tag world-cancer-series
article thumbnail

Clover biopharmaceuticals raises $230 M; BrainStorm after ALS; BARDA grants $5.65 M LightDeck for SARS-CoV-2 antigen test; Libtayo for first-line advanced NSCLC subset

Delveinsight

Clover Biopharmaceuticals announced the completion of an oversubscribed $230 million Series C financing, summing total capital raised by the company during the last year over USD 400 million. The Series C round was co-led by GL Ventures and Temasek, with participation from Oceanpine Capital, OrbiMed, and existing investor Delos Capital.

article thumbnail

Q&A: A decade on, what’s next for CAR-T therapies?

Pharmaceutical Technology

But access to these treatments continues to remain limited due to high price tags and variable availability across regions. And coming back to the ISCT, we have a series of roundtables that go beyond the traditional didactic sessions, which address the issue of patient access. We must approach this on several fronts.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

New to ELRIG Drug Discovery 2022: Tech Theatre supported by DDW

Drug Discovery World

A series of short seminars focused on automation and technology will be available to visitors at Drug Discovery 2022 which takes place at the ExCel, London 4 and 5 October. The post New to ELRIG Drug Discovery 2022: Tech Theatre supported by DDW appeared first on Drug Discovery World (DDW).

Drugs 52
article thumbnail

A history of Johnson & Johnson

pharmaphorum

By most measures the single largest pharma company in the world, US-based Johnson & Johnson (J&J) is also arguably one of the most well-known drugmakers among the general public. . Following World War II, Ethicon’s market share in surgical sutures rose from 15% to 70% worldwide. joined the J&J Family of Companies.

Sales 113
article thumbnail

What to expect from PEGS Europe 2023: Day 3

Drug Discovery World

Shohei Koide, PhD, Professor, Biochemistry & Molecular Pharmacology, New York University School of Medicine; Perlmutter Cancer Center, NYU Langone Health, on: ‘Creating and targeting cancer-specific neoantigens by design’. Jeremy Fry, Dr, Director of Sales, ProImmune, on: ‘Mastering immunogenicity and biologics development’.

Protein 59
article thumbnail

Leveraging flow cytometry in drug discovery 

Drug Discovery World

The main principle involves a well-defined light source such as that produced by lasers that excites fluorescent tags bound to the cells or particles present in a sample. The post Leveraging flow cytometry in drug discovery appeared first on Drug Discovery World (DDW).

Reagent 52
article thumbnail

Merck KGaA raises full-year forecast; Perlmutter’s new gig tackles ‘undruggable targets’

The Pharma Data

Now its failures are threatening much of the world ( Reuters ). The long wait for Cel-Sci to finally admit its cancer drug doesn’t work ( STAT ). Day One pivots to an IPO for more funding to back its work in pediatric cancer ( Endpoints ). Coronavirus Pandemic. Medtech.